Study on Predictive Factors of Anti-Angiogenesis Therapy Combined with Neoadjuvant Chemotherapy for Phase IIIA Non-Small Cell Lung Cancer

被引：0
作者：
Wang, Changli [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
anti-angiogenesis; neoadjuvant chemotherapy; non-small cell lung cancer; Endostar; predictive factors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PUB036
引用
收藏
页码：S771 / S771
页数：1
相关论文
共 50 条
  • [11] Non-small cell lung cancer neoadjuvant chemotherapy: the benefits of gemcitabine
    Van Zandwijk, N
    ANTI-CANCER DRUGS, 2001, 12 : S15 - S19
  • [12] Neoadjuvant chemotherapy for resectable non-small cell lung cancer
    Finkelstein, EI
    Urschel, JD
    Takita, H
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1997, 16 (04) : 437 - 439
  • [13] The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update
    Liza C. Villaruz
    Mark A. Socinski
    Current Oncology Reports, 2015, 17
  • [14] The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update
    Villaruz, Liza C.
    Socinski, Mark A.
    CURRENT ONCOLOGY REPORTS, 2015, 17 (06)
  • [15] Neoadjuvant chemotherapy in non-small cell lung cancer: current state and future
    Mellas, N.
    Elmesbahi, O.
    Masbah, O.
    Errihani, H.
    BULLETIN DU CANCER, 2010, 97 (02) : 211 - 223
  • [16] Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
    Chen, Caroline Y.
    Fares, Charlene M.
    Shin, Daniel Sanghoon
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [17] Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
    Dai, Fuqiang
    Wu, Xiaoli
    Wang, Xintian
    Li, Kunkun
    Wang, Yingjian
    Shen, Cheng
    Zhou, Jinghai
    Niu, Huijun
    Deng, Bo
    Tan, Qunyou
    Wang, Ruwen
    Guo, Wei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [18] Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
    Caroline Y. Chen
    Charlene M. Fares
    Daniel Sanghoon Shin
    Journal of Medical Case Reports, 15
  • [19] Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
    Qiu, Lupeng
    Zhao, Xiao
    Shi, Weiwei
    Sun, Shengjie
    Zhang, Guoqing
    Sun, Qiong
    Meng, Jing
    Xiong, Qi
    Qin, Boyu
    Jiao, Shunchang
    MEDICINE, 2020, 99 (24) : E20545
  • [20] Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
    Han, Ruoshuang
    Guo, Haoyue
    Shi, Jinpeng
    Zhao, Sha
    Jia, Yijun
    Liu, Xiaozhen
    Liu, Yiwei
    Cheng, Lei
    Zhao, Chao
    Li, Xuefei
    Zhou, Caicun
    BMC MEDICINE, 2024, 22 (01)
12345